Induced Pluripotent Stem Cells Market Size is Expected to Grow at a CAGR of 9.4% and Reach USD 4.6 billion by 2034: Transparency Market Research Inc.

Induced pluripotent stem cells are experiencing strong growth due to rising research into disease models and drug discovery. 

WILMINGTON, Del., July 11, 2024 /PRNewswire/ — The global induced pluripotent stem cells industry was worth US$ 1.7 billion in 2023. By 2034, it is estimated to reach US$ 4.6 billion, expanding at a CAGR of 9.4% between 2024 and 2034. As reprogramming strategies improve, iPSCs become more feasible for many applications and more attractive to buyers.

The utilization of iPSCs in drug discovery and disease modeling is being accelerated by excessive-throughput screening technologies. Aside from heart disease, liver failure, and diabetes, iPSCs are capable of creating organ replacements. By doing so, the donor organ shortage can be addressed and the impact on affected people can be enhanced. Several wound recuperation treatments are possible with iPSCs, including those that treat excessive burns and chronic ulcers.

Cells from iPSCs can be used to develop new immunotherapies, such as CAR-T mobile treatments for cancer. Depending on the patient’s immune system, these treatment plans may enhance effectiveness and reduce side effects. Besides Parkinson’s disorder, spinal cord injuries, and macular degeneration, iPSCs can also be used to update damaged or diseased cells.

Download Sample of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30530

Induced Pluripotent Stem Cells Market Report Scope:

Global Induced Pluripotent Stem Cells Market: Competitive Landscape

iPSC-based therapies can be commercialized more quickly with partnerships among educational institutions and biotech/pharmaceutical companies. By utilizing global studies networks and consortia, information can be shared, protocols are standardized, and problems can be collectively solved, propelling forward the iPSC industry.

 Key Players Profiled

Axol BioscienceCynata Therapeutics LimitedEvotec SEFate TherapeuticsFUJIFILM Cellular Dynamics Inc.NcardiaLizarBio TherapeuticsREPROCELL GlobalSumitomo Dainippon Pharma Company LimitedTakara Bio USA Inc.Thermo Fisher ScientificVertex Pharmaceuticals

Key Developments

In May 2023, Fujifilm Cellular Dynamics, a global provider of induced pluripotent stem cells (iPSC), and Novo Nordisk signed an agreement to jointly develop and commercialize iPSC-derived cell therapies targeting serious chronic conditions.In October 2023, Axol Bioscience and Sygnature Discovery were involved in a scientific collaboration to incorporate human induced pluripotent stem cells-derived microglia into vitroscreening workflows for high-content imaging.

Key Findings of the Market Report

As of 2023, diagnostic centers held the largest share of the market.In 2023, North America held the dominant position in the market.In terms of cell type, fibroblasts are likely to be the primary driver of induced pluripotent stem cell demand.The use of stem cells for regenerative medicine is expected to increase in the near future.A growing number of pharmaceutical and biotechnology companies are expected to expand their offerings. 

Global Induced Pluripotent Stem Cells Market: Growth Drivers

The development of gene-enhancing technologies, including CRISPR-Cas9, has improved the production and precision of iPSCs significantly. By using these technologies, genetic defects can be corrected, and illness fashions can be introduced.In recent years, technology has improved the ease and safety of converting somatic cells into iPSCs, allowing them to be used in medical procedures. Manufacturing and analyzing iPSCs have been streamlined by automation and high-throughput screening technology, enabling big-scale research and cutting costs.The iPSCs are crucial to growing regenerative therapies for damaged tissues and organs. A capacity solution has been developed for coronary heart disease, spinal cord injuries, and neurodegenerative diseases. In oncology and chronic illness management, iPSCs can be derived from a patient’s own cells to minimize the chance of immune rejection.Using iPSCs, researchers can build disease-specific mobile models, allowing them to study disease mechanisms and screen potential drugs more effectively. Using iPSCs reduces the reliance on animal models and improves the predictability of human responses to toxicology.

 Explore Sample of the Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30530 

Global Induced Pluripotent Stem Cells Market: Regional Landscape

North America has numerous international-renowned research institutions and universities that are at the leading edge of stem cell studies. IPSCs are used in basic studies, drug discovery, and disease modeling by these establishments. The National Institutes of Health (NIH) together with government groups provide significant funding for research on iPSCs.iPSCs have been the subject of an excessive number of clinical trials throughout North America, indicating their ability to grow new therapies. Several successful trials and future cures are expected to increase demand. A stem cell bank or repository in the status quo facilitates the use of iPSCs for therapeutic and research purposes.The iPSC is a viable alternative to embryonic stem cells that bypasses many of the ethical issues associated with embryonic stem cells. Increasing public awareness about stem cell research and its benefits increases support for iPSC-based improvements.

Global Induced Pluripotent Stem Cells Market: Segmentation

Cell Type

HepatocytesFibroblastsKeratinocytesOthers (Neurons, etc.)

Application

Drug DevelopmentRegenerative MedicineToxicity TestingTissue EngineeringCell TherapyDisease Modeling

End User

HospitalsDiagnostic CentersPharmaceutical & Biotechnology CompaniesContract Research OrganizationsOthers (Academic & Research Institutes, etc.)

Region

North AmericaEuropeAsia PacificLatin AmericaMiddle East & Africa

Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=30530&ltype=S 

More Trending Report by Transparency Market Research:

Geriatric Care Services Market to Grow at a 7.3% CAGR from 2023 to 2028, reaching US$ 0.7 billion: TMR ReportPreeclampsia Diagnostics Market Set to Reach USD 2.3 Billion by 2031, growing at a CAGR of 3.8%: TMR ReportMedical Case Management Market is expected to grow at a CAGR of 6.1% from 2024 to 2034 and reach US$ 12.3 Bn by the end of 2034.Lucid Dreaming Devices Market is expected to grow at a CAGR of 5.1% from 2024 to 2034 and reach US$ 196.8 Mn by the end of 2034.

About Transparency Market Research 

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. 

Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com  
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn | Twitter | Blog | YouTube

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/induced-pluripotent-stem-cells-market-size-is-expected-to-grow-at-a-cagr-of-9-4-and-reach-usd-4-6-billion-by-2034-transparency-market-research-inc-302194822.html